Please login to the form below
STING
This page shows the latest STING news and features for those working in and with pharma, biotech and healthcare.
Bayer signs €250m pact with India’s Curadev for STING drugs
started working on STING drugs with potential in auto-immune and inflammatory diseases. ... Eli Lilly, for example, paid $12m upfront in a $620 million deal with Aduro Biotech at the end of 2018 for STING inhibitors, focusing on autoimmune diseases.
Latest news
-
AbbVie cures STING fever with Mavupharma acquisition
Novartis paid $200m upfront for rights to Aduro’s STING programme in 2015. ... pipeline. Meanwhile, Mavupharma isn’t the only company trying to develop small-molecule STING agonists.
-
Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy
BMS’ interest was mainly on IFM’s STING and NLRP3 agonists and their potential in boosting immune responses to tumours.
-
New ‘voluntary’ UK pricing deal caps growth, but promises faster uptake
salve its sting. .
-
Dynavax is ‘deal-ready’ after solid ESMO data; analyst
STING ‘has not stung’. Merck would be an obvious choice for that role, and the analysts also suggest that a deal for SD-101 could be more likely given a lacklustre ... also that the STING agonists were speculated to be more potent based on biology
-
A look ahead to key trial readouts at ESMO
Looking at some of the new mechanisms on show, Merck/MSD will also have the first clinical results for its STING activator MK-1454, Adaptimmune will have first-in-human results
AbbVie cures STING fever with Mavupharma acquisition
Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy
New ‘voluntary’ UK pricing deal caps growth, but promises faster uptake
Dynavax is ‘deal-ready’ after solid ESMO data; analyst
A look ahead to key trial readouts at ESMO
More from news
Approximately 2 fully matching, plus 18 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
Among the plethora in the pipeline, Aurigene and BMS are looking at PD-1 inhibitors that can be dosed orally, Novartis, iTeos and Aduro are developing STING agonists that can
-
Live boulder, live louder
It’s like deconstructing a joke; by the end, the punchline loses its sting.
-
Medius Deal Watch table for March 2015
825. Aduro / Novartis. Licence and collaboration. Preclinical cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway.
-
Pharma deals in March 2015
One such example is Novartis which has CAR-T and checkpoint inhibitor programmes and has now added Aduro's STING (Stimulator of Interferon Genes) technology as an additional string to its ... bow. Aduro has a number of preclinical small molecule cyclic
Cancer immunotherapy: What's on the horizon?
Live boulder, live louder
Medius Deal Watch table for March 2015
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Frontera Group
STING - brand / diseases modules. PRECIS - clinical study modules.
Frontera Group
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
CEO Pricing & Market Access, UK
-
Six figure salary
-
Omnichannel Strategy Consultant
-
Competitive Salary
-
CEO, Head of Health, UK
-
Six figure salary
-
Senior Account Manager
-
Competitive salary offered
- Valneva COVID-19 vaccine more effective than AZ
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
- Biogen's ALS drug tofersen misses phase 3 endpoint
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s COVID-19 antiviral under review in Europe by EMA
- AZ’s Imfinzi boosts survival in biliary tract cancer
- MAKING THE FIRST YEAR MATTER
- Merck receives first breast cancer approval in Europe for Keytruda
- Benefits of COVID-19 vaccine in younger children outweigh risks, says FDA
- Call for industry innovators to join working group
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
- Curb your conservatism: can pharma ditch its cautious approach to creativity in comms?
- Amgen strikes $240m autoimmune deal with Evoq Therapeutics
- Award-winning health agency 90TEN launches in the US
PMHub
Mind+Matter
We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...
Latest intelligence
- The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
- The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
- Mind the Gap – Challenging Immunisation Apathy and Misinformation
- world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
- Towards Better HCP Engagement – An Email Masterclass
- 6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....
